help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by KAVURU, M. S.
Right arrow Articles by STOLLER, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KAVURU, M. S.
Right arrow Articles by STOLLER, J. K.

Am. J. Respir. Crit. Care Med., Volume 161, Number 4, April 2000, 1143-1148

Exogenous Granulocyte-Macrophage Colony-Stimulating Factor Administration for Pulmonary Alveolar Proteinosis

MANI S. KAVURU, EUGENE J. SULLIVAN, RITA PICCIN, MARY JANE THOMASSEN, and JAMES K. STOLLER

Department of Pulmonary and Critical Care Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio

Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of lipoproteinaceous material within the alveoli. Recent data suggest that granulocyte-macrophage colony- stimulating factor (GM-CSF) may be involved in the pathogenesis of PAP. To extend this understanding and clarify whether GM-CSF replacement confers benefit, we report the preliminary results for the first four patients in an open-label study of GM-CSF treatment for moderate exacerbation of PAP. All four patients had idiopathic PAP confirmed by open lung biopsy. Subcutaneous GM-CSF was self-administered once daily for 12 wk (dose escalation from 3 to 9 µg/kg/d). Response was assessed from symptom scores, arterial blood gas measurements, pulmonary function testing, and chest radiographs. Three of the four patients experienced symptomatic, physiologic, and radiographic improvement with GM-CSF. Responders experienced sufficient improvement in oxygenation as to eliminate the need for supplemental oxygen, and one patient was removed from the waiting list for lung transplantation. Improved oxygenation was not apparent until 8 to 12 wk after the start of therapy. Notably, expected increases in the peripheral white blood cell count did not occur, suggesting lack of a hematopoietic response to exogenous GM-CSF in PAP. We conclude that GM-CSF appears to benefit a subset of patients with adult PAP, and may represent an alternative to whole-lung lavage in treating the disease.




This article has been cited by other articles:


Home page
 ChestHome page
S. R. Greenhill and D. N. Kotton
Pulmonary Alveolar Proteinosis: A Bench-to-Bedside Story of Granulocyte-Macrophage Colony-Stimulating Factor Dysfunction
Chest, August 1, 2009; 136(2): 571 - 577.
[Abstract] [Full Text] [PDF]

Home page
 J. Lipid Res.Home page
M. J. Thomassen, B. P. Barna, A. G. Malur, T. L. Bonfield, C. F. Farver, A. Malur, H. Dalrymple, M. S. Kavuru, and M. Febbraio
ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis
J. Lipid Res., December 1, 2007; 48(12): 2762 - 2768.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. E. Dexter, G. P. Cosgrove, and I. S. Douglas
Managing a Rare Condition Presenting With Intractable Hypoxemic Respiratory Failure
Chest, January 1, 2007; 131(1): 320 - 327.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. E. O. Baleeiro, P. J. Christensen, S. B. Morris, M. P. Mendez, S. E. Wilcoxen, and R. Paine III
GM-CSF and the impaired pulmonary innate immune response following hyperoxic stress
Am J Physiol Lung Cell Mol Physiol, December 1, 2006; 291(6): L1246 - L1255.
[Abstract] [Full Text] [PDF]

Home page
 Chronic Respiratory DiseaseHome page
O C Ioachimescu and M S Kavuru
Pulmonary alveolar proteinosis
Chronic Respiratory Disease, July 1, 2006; 3(3): 149 - 159.
[Abstract] [PDF]

Home page
 ChestHome page
S. B. Venkateshiah, T. D. Yan, T. L. Bonfield, M. J. Thomassen, M. Meziane, C. Czich, and M. S. Kavuru
An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis.
Chest, July 1, 2006; 130(1): 227 - 237.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
F-C Lin, G-D Chang, M-S Chern, Y-C Chen, and S-C Chang
Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis
Thorax, June 1, 2006; 61(6): 528 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M. E. Wylam, R. Ten, U. B. S. Prakash, H. F. Nadrous, M. L. Clawson, and P. M. Anderson
Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis.
Eur. Respir. J., March 1, 2006; 27(3): 585 - 593.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
T. L. Bonfield, C. M. Swaisgood, B. P. Barna, C. F. Farver, M. S. Kavuru, and M. J. Thomassen
Elevated gelatinase activity in pulmonary alveolar proteinosis: role of macrophage-colony stimulating factor
J. Leukoc. Biol., January 1, 2006; 79(1): 133 - 139.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
T. L. Bonfield, N. John, B. P. Barna, M. S. Kavuru, M. J. Thomassen, and B. Yen-Lieberman
Multiplexed Particle-Based Anti-Granulocyte Macrophage Colony Stimulating Factor Assay Used as Pulmonary Diagnostic Test
Clin. Vaccine Immunol., July 1, 2005; 12(7): 821 - 824.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. Tazawa, E. Hamano, T. Arai, H. Ohta, O. Ishimoto, K. Uchida, M. Watanabe, J. Saito, M. Takeshita, Y. Hirabayashi, et al.
Granulocyte-Macrophage Colony-Stimulating Factor and Lung Immunity in Pulmonary Alveolar Proteinosis
Am. J. Respir. Crit. Care Med., May 15, 2005; 171(10): 1142 - 1149.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. Perez IV and R. M. Rogers
Enhanced Alveolar Clearance With Chest Percussion Therapy and Positional Changes During Whole-Lung Lavage for Alveolar Proteinosis
Chest, June 1, 2004; 125(6): 2351 - 2356.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
C. Morgan
The benefits of whole lung lavage in pulmonary alveolar proteinosis
Eur. Respir. J., April 1, 2004; 23(4): 503 - 505.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Beccaria, M. Luisetti, G. Rodi, A. Corsico, M.C. Zoia, S. Colato, P. Pochetti, A. Braschi, E. Pozzi, and I. Cerveri
Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis
Eur. Respir. J., April 1, 2004; 23(4): 526 - 531.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
B. C. Trapnell, J. A. Whitsett, and K. Nakata
Pulmonary Alveolar Proteinosis
N. Engl. J. Med., December 25, 2003; 349(26): 2527 - 2539.
[Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
T. L. Bonfield, C. F. Farver, B. P. Barna, A. Malur, S. Abraham, B. Raychaudhuri, M. S. Kavuru, and M. J. Thomassen
Peroxisome Proliferator-Activated Receptor-{gamma} Is Deficient in Alveolar Macrophages from Patients with Alveolar Proteinosis
Am. J. Respir. Cell Mol. Biol., December 1, 2003; 29(6): 677 - 682.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. L. Bonfield, B. Raychaudhuri, A. Malur, S. Abraham, B. C. Trapnell, M. S. Kavuru, and M. J. Thomassen
PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor
Am J Physiol Lung Cell Mol Physiol, November 1, 2003; 285(5): L1132 - L1136.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. S. Kavuru, T. L. Bonfield, M. J. Thomassen, J. F. Seymour, and J. J. Presneill
Plasmapheresis, GM-CSF, and alveolar proteinosis
Am. J. Respir. Crit. Care Med., April 1, 2003; 167(7): 1036 - 1037.
[Full Text]

Home page
 ThoraxHome page
J F Seymour, I R Doyle, K Nakata, J J Presneill, O D Schoch, E Hamano, K Uchida, R Fisher, and A R Dunn
Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis
Thorax, March 1, 2003; 58(3): 252 - 257.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Cell Mol. Bio.Home page
T. L. Bonfield, D. Russell, S. Burgess, A. Malur, M. S. Kavuru, and M. J. Thomassen
Autoantibodies against Granulocyte Macrophage Colony-Stimulating Factor Are Diagnostic for Pulmonary Alveolar Proteinosis
Am. J. Respir. Cell Mol. Biol., October 1, 2002; 27(4): 481 - 486.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. S. Kavuru and M. Popovich
Therapeutic Whole Lung Lavage : A Stop-Gap Therapy for Alveolar Proteinosis
Chest, October 1, 2002; 122(4): 1123 - 1124.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. F. Seymour and J. J. Presneill
Pulmonary Alveolar Proteinosis: Progress in the First 44 Years
Am. J. Respir. Crit. Care Med., July 15, 2002; 166(2): 215 - 235.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Tuberculosis, Lung Infections, and Interstitial Lung Disease in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 15, 2001; 164(10): 1774 - 1788.
[Full Text] [PDF]

Home page
 ThoraxHome page
R M Barraclough and A J Gillies
Pulmonary alveolar proteinosis: a complete response to GM-CSF therapy
Thorax, August 1, 2001; 56(8): 664 - 665.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. S. Carraway, C. A. Piantadosi, and J. R. Wright
Alveolar proteinosis: a disease of mice and men
Am J Physiol Lung Cell Mol Physiol, March 1, 2001; 280(3): L377 - L378.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  ATS Coding and Billing Quarterly